Literature DB >> 26290146

Reply to the Letter to the Editor.

Melanie Kripp1, Salah-Eddin Al-Batran2, Ralf-Dieter Hofheinz3.   

Abstract

Mesh：

Year:  2015        PMID： 26290146     DOI： 10.1007/s10120-015-0532-x

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


× No keyword cloud information.
  5 in total

1.  Interpreting the significance of changes in health-related quality-of-life scores.

Authors:  D Osoba; G Rodrigues; J Myles; B Zee; J Pater
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

2.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

3.  Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Melanie Kripp; Salah-Eddin Al-Batran; Johanna Rosowski; Claudia Pauligk; Nils Homann; Jörg Thomas Hartmann; Markus Moehler; Ralf-Dieter Hofheinz
Journal:  Gastric Cancer       Date:  2013-02-28       Impact factor: 7.370

4.  The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

Authors:  Salah-Eddin Al-Batran; Claudia Pauligk; Nils Homann; Jörg T Hartmann; Markus Moehler; Stephan Probst; Volker Rethwisch; Jan Stoehlmacher-Williams; Nicole Prasnikar; Stephan Hollerbach; Carsten Bokemeyer; Rolf Mahlberg; Ralf D Hofheinz; Kim Luley; Frank Kullmann; Elke Jäger
Journal:  Eur J Cancer       Date:  2012-10-11       Impact factor: 9.162

5.  Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.

Authors:  Jaffer A Ajani; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Lucile Awad; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.